<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39354971</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2673-8880</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in nuclear medicine (Lausanne, Switzerland)</Title><ISOAbbreviation>Front Nucl Med</ISOAbbreviation></Journal><ArticleTitle>Development and evaluation of an <sup>18</sup>F-labeled nanobody to target SARS-CoV-2's spike protein.</ArticleTitle><Pagination><StartPage>1033697</StartPage><MedlinePgn>1033697</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1033697</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnume.2022.1033697</ELocationID><Abstract><AbstractText>COVID-19, caused by the SARS-CoV-2 virus, has become a global pandemic that is still present after more than two years. COVID-19 is mainly known as a respiratory disease that can cause long-term consequences referred to as long COVID. Molecular imaging of SARS-CoV-2 in COVID-19 patients would be a powerful tool for studying the pathological mechanisms and viral load in different organs, providing insights into the disease and the origin of long-term consequences and assessing the effectiveness of potential COVID-19 treatments. Current diagnostic methods used in the clinic do not allow direct imaging of SARS-CoV-2. In this work, a nanobody (NB) - a small, engineered protein derived from alpacas - and an Fc-fused NB which selectively target the SARS-CoV-2 Spike protein were developed as imaging agents for positron emission tomography (PET). We used the tetrazine ligation to <sup>18</sup>F-label the NB under mild conditions once the NBs were successfully modified with <i>trans-</i>cyclooctenes (TCOs). We confirmed binding to the Spike protein by SDS-PAGE. Dynamic PET scans in rats showed excretion through the liver for both constructs. Future work will evaluate <i>in vivo</i> binding to the Spike protein with our radioligands.</AbstractText><CopyrightInformation>&#xa9; 2022 Lopes van den Broek, Garc&#xed;a-V&#xe1;zquez, Andersen, Valenzuela-Nieto, Shalgunov, Battisti, Schwefel, Modhiran, Kramer, Cheuquemilla, Jara, Salinas-Varas, Amarilla, Watterson, Rojas-Fernandez and Herth.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lopes van den Broek</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-V&#xe1;zquez</LastName><ForeName>Roc&#xed;o</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Ida Vang</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valenzuela-Nieto</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Medicine, Faculty of Medicine &amp; Center for Interdisciplinary Studies on the Nervous System, CISNE, Universidad Austral de Chile, Valdivia, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shalgunov</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Battisti</LastName><ForeName>Umberto M</ForeName><Initials>UM</Initials><AffiliationInfo><Affiliation>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwefel</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Medical Physics and Biophysics, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin and Humboldt-Universit&#xe4;t zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modhiran</LastName><ForeName>Naphak</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Vasko</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Positronpharma SA, Providencia, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheuquemilla</LastName><ForeName>Yorka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Medicine, Faculty of Medicine &amp; Center for Interdisciplinary Studies on the Nervous System, CISNE, Universidad Austral de Chile, Valdivia, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jara</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Medicine, Faculty of Medicine &amp; Center for Interdisciplinary Studies on the Nervous System, CISNE, Universidad Austral de Chile, Valdivia, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salinas-Varas</LastName><ForeName>Constanza</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Medicine, Faculty of Medicine &amp; Center for Interdisciplinary Studies on the Nervous System, CISNE, Universidad Austral de Chile, Valdivia, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amarilla</LastName><ForeName>Alberto A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watterson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas-Fernandez</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Medicine, Faculty of Medicine &amp; Center for Interdisciplinary Studies on the Nervous System, CISNE, Universidad Austral de Chile, Valdivia, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berking Biotechnology, Valdivia, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herth</LastName><ForeName>Matthias M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Physiology, Nuclear Medicine &amp; PET, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Nucl Med</MedlineTA><NlmUniqueID>9918470388806676</NlmUniqueID><ISSNLinking>2673-8880</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">alpaca</Keyword><Keyword MajorTopicYN="N">biodistribution</Keyword><Keyword MajorTopicYN="N">nanobodies</Keyword><Keyword MajorTopicYN="N">tetrazine ligation</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39354971</ArticleId><ArticleId IdType="pmc">PMC11440877</ArticleId><ArticleId IdType="doi">10.3389/fnume.2022.1033697</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thanh Le T, Andreadakis Z, Kumar A, G&#xf3;mez Rom&#xe1;n R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. (2020) 19(5):305&#x2013;6. 10.1038/d41573-020-00073-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-020-00073-5</ArticleId><ArticleId IdType="pubmed">32273591</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. (2020) 26(5):483&#x2013;95. 10.1016/j.molmed.2020.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2020.02.008</ArticleId><ArticleId IdType="pmc">PMC7118693</ArticleId><ArticleId IdType="pubmed">32359479</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. WHO Coronavirus (COVID-19) Dashbord (2022).</Citation></Reference><Reference><Citation>Agdamag ACC, Edmiston JB, Charpentier V, Chowdhury M, Fraser M, Maharaj VR, et al. Update on COVID-19 myocarditis. Medicina (Kaunas). (2020) 56(12)1&#x2013;10. 10.3390/medicina56120678</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina56120678</ArticleId><ArticleId IdType="pmc">PMC7764165</ArticleId><ArticleId IdType="pubmed">33317101</ArticleId></ArticleIdList></Reference><Reference><Citation>Barhoum P, Pineton de Chambrun M, Dorgham K, Kerneis M, Burrel S, Quentric P, et al. Phenotypic heterogeneity of fulminant COVID-19&#x2013;related myocarditis in adults. J Am Coll Cardiol. (2022) 80(4):299&#x2013;312. 10.1016/j.jacc.2022.04.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.04.056</ArticleId><ArticleId IdType="pmc">PMC9291241</ArticleId><ArticleId IdType="pubmed">35863846</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinayagam S, Sattu K. SARS-CoV-2 and coagulation disorders in different organs. Life Sci. (2020) 260:118431. 10.1016/j.lfs.2020.118431</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118431</ArticleId><ArticleId IdType="pmc">PMC7490584</ArticleId><ArticleId IdType="pubmed">32946915</ArticleId></ArticleIdList></Reference><Reference><Citation>Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. (2020) 95(7):834&#x2013;47. 10.1002/ajh.25829</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25829</ArticleId><ArticleId IdType="pmc">PMC7262337</ArticleId><ArticleId IdType="pubmed">32282949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. (2020) 31(5):1003&#x2013;8. 10.1111/jce.14479</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.14479</ArticleId><ArticleId IdType="pmc">PMC7262150</ArticleId><ArticleId IdType="pubmed">32270559</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. (2020) 143:2&#x2013;37. 10.1093/brain/awaa240</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan&#xe1;-Cuevas P, Salles-G&#xe1;ndara P, Rojas-Fernandez A, Salinas-Rebolledo C, Mil&#xe1;n-Sol&#xe9; A. The potential role of SARS-COV-2 in the pathogenesis of Parkinson's Disease. Front Neurol. (2020) 11:1044. 10.3389/fneur.2020.01044</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.01044</ArticleId><ArticleId IdType="pmc">PMC7527541</ArticleId><ArticleId IdType="pubmed">33041985</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. (2020) 579(7798):265&#x2013;9. 10.1038/s41586-020-2008-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Kream RM, Stefano GB. Long-Term respiratory and neurological sequelae of COVID-19. Med Sci Monit. (2020) 26:e928996. 10.12659/MSM.928996</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.928996</ArticleId><ArticleId IdType="pmc">PMC7643287</ArticleId><ArticleId IdType="pubmed">33177481</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA - J Am Med Assoc. (2020) 323(18):1824&#x2013;36. 10.1001/jama.2020.6019</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6019</ArticleId><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. (2020) 20(5):269&#x2013;70. 10.1038/s41577-020-0308-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId><ArticleId IdType="pmc">PMC7143200</ArticleId><ArticleId IdType="pubmed">32273594</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeples L. Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci U S A. (2020) 117(15):8218&#x2013;21. 10.1073/pnas.2005456117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005456117</ArticleId><ArticleId IdType="pmc">PMC7165470</ArticleId><ArticleId IdType="pubmed">32229574</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo-Aguado M, Corredor-Orlandelli D, Carrillo-Mart&#xed;nez JC, Gonzalez-Cornejo M, Pineda-Mateus E, Rojas C, et al. Association between the LZTFL1 rs11385942 polymorphism and COVID-19 severity in Colombian population. Front Med (Lausanne). (2022) 9:910098. 10.3389/fmed.2022.910098</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.910098</ArticleId><ArticleId IdType="pmc">PMC9251207</ArticleId><ArticleId IdType="pubmed">35795626</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira E, Felipe S, de Freitas R, Ara&#xfa;jo V, Soares P, Ribeiro J, et al. ABO Blood group and link to COVID-19: a comprehensive review of the reported associations and their possible underlying mechanisms. Microb Pathog. (2022) 169:105658. 10.1016/j.micpath.2022.105658</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2022.105658</ArticleId><ArticleId IdType="pmc">PMC9233352</ArticleId><ArticleId IdType="pubmed">35764188</ArticleId></ArticleIdList></Reference><Reference><Citation>Severe Covid-19 GWAS Group. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, et al. Genomewide association study of severe COVID-19 with respiratory failure. N Engl J Med. (2020) 383(16):1522&#x2013;34. 10.1056/NEJMoa2020283</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2020283</ArticleId><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;ter J, Pallerla SR, Meyer CG, Casadei N, Sonnabend M, Peter S, et al. Host genetic loci LZTFL1 and CCL2 associated with SARS-CoV-2 infection and severity of COVID-19. Int J Infect Dis. (2022) 122:427&#x2013;36. 10.1016/j.ijid.2022.06.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.06.030</ArticleId><ArticleId IdType="pmc">PMC9222649</ArticleId><ArticleId IdType="pubmed">35753602</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I, Falf&#xe1;n-Valencia R. Genetics insight for COVID-19 susceptibility and severity: a review. Front Immunol. (2021) 12:622176. 10.3389/fimmu.2021.622176</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.622176</ArticleId><ArticleId IdType="pmc">PMC8047200</ArticleId><ArticleId IdType="pubmed">33868239</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil MM, Tremoleda JL, Bayomy TB, Gsell W. Molecular SPECT imaging: an overview. Int J Mol Imaging. (2011) 2011:1&#x2013;15. 10.1155/2011/796025</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/796025</ArticleId><ArticleId IdType="pmc">PMC3094893</ArticleId><ArticleId IdType="pubmed">21603240</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu S, Kwee TC, Surti S, Akin EA, Yoo D, Alavi A. Fundamentals of PET and PET/CT imaging. Ann N Y Acad Sci. (2011) 1228(1):1&#x2013;18. 10.1111/j.1749-6632.2011.06077.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2011.06077.x</ArticleId><ArticleId IdType="pubmed">21718318</ArticleId></ArticleIdList></Reference><Reference><Citation>Piel M, Vernaleken I, R&#xf6;sch F. Positron emission tomography in CNS drug discovery and drug monitoring. J Med Chem. (2014) 57:9232&#x2013;58. 10.1021/jm5001858</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm5001858</ArticleId><ArticleId IdType="pubmed">25144329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. (2008) 108:1501&#x2013;16. 10.1021/cr0782426</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cr0782426</ArticleId><ArticleId IdType="pubmed">18426240</ArticleId></ArticleIdList></Reference><Reference><Citation>Theek B, Rizzo LY, Ehling J, Kiessling F, Lammers T. The theranostic path to personalized nanomedicine. Clin Transl Imaging. (2014) 2:67&#x2013;76. 10.1007/s40336-014-0051-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40336-014-0051-5</ArticleId><ArticleId IdType="pmc">PMC4031631</ArticleId><ArticleId IdType="pubmed">24860796</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamey G, Sch&#xe4;ferhoff M, Hatchett R, Pate M, Zhao F, McDade KK. Ensuring global access to COVID-19 vaccines. The Lancet. (2020) 395(10234):1405&#x2013;6. 10.1016/S0140-6736(20)30763-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30763-7</ArticleId><ArticleId IdType="pmc">PMC7271264</ArticleId><ArticleId IdType="pubmed">32243778</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&amp;D. Science (1979). (2020) 368(6494):948&#x2013;50. 10.1126/science.abc5312</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc5312</ArticleId><ArticleId IdType="pubmed">32393526</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong D, Tang Z, Wang S, Hui H, Gong L, Lu Y, et al. The role of imaging in the detection and management of COVID-19: a review. IEEE Rev Biomed Eng. (2020) 14:1&#x2013;14. 10.1109/RBME.2020.2990959</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/RBME.2020.2990959</ArticleId><ArticleId IdType="pubmed">32356760</ArticleId></ArticleIdList></Reference><Reference><Citation>Manna S, Wruble J, Maron SZ, Toussie D, Voutsinas N, Finkelstein M, et al. COVID-19: a multimodality review of radiologic techniques, clinical utility, and imaging features. Radiol Cardiothorac Imaging. (2020) 2(3):1&#x2013;28. 10.1148/ryct.2020200210</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/ryct.2020200210</ArticleId><ArticleId IdType="pmc">PMC7325394</ArticleId><ArticleId IdType="pubmed">33778588</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalan R, Bornstein SR, El-armouche A, Rodionov RN, Markov A, Wielockx B, et al. The ACE-2 in COVID-19&#x202f;: foe or friend? Horm Metab Res. (2020) 51:257&#x2013;63. 10.1055/a-1155-0501</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1155-0501</ArticleId><ArticleId IdType="pmc">PMC7339082</ArticleId><ArticleId IdType="pubmed">32340044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen JL, Herth MM. In vivo imaging in drug discovery. In: Str&#xf8;mgaard K, Korgsgaard-Larsen P, Madsen U, editors. Textbook of drug design and discovery. Fifth. Boca Raton, FL, USA: CRC Press; (2017). p. 119&#x2013;35.</Citation></Reference><Reference><Citation>Nieto GV, Jara R, Himelreichs J, Salinas C, Pinto T, Cheuquemilla Y, et al.  http://biorxiv.org/content/early/2020/06/10/2020.06.09.137935.abstract Fast isolation of sub-nanomolar affinity alpaca nanobody against the spike RBD of SARS-CoV-2 by combining bacterial display and a simple single-step density gradient selection. bioRxiv. (2020):1&#x2013;32. Available at:</Citation></Reference><Reference><Citation>Gai J, Ma L, Li G, Zhu M, Qiao P, Li X, et al. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. MedComm (Beijing). (2021) 2(1):101&#x2013;13. 10.1002/mco2.60</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.60</ArticleId><ArticleId IdType="pmc">PMC8013425</ArticleId><ArticleId IdType="pubmed">33821254</ArticleId></ArticleIdList></Reference><Reference><Citation>Nambulli S, Xiang Y, Tilston-Lunel NL, Rennick LJ, Sang Z, Klimstra WB, et al. Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci Adv. (2021) 7(22):1&#x2013;10. 10.1126/sciadv.abh0319</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abh0319</ArticleId><ArticleId IdType="pmc">PMC8153718</ArticleId><ArticleId IdType="pubmed">34039613</ArticleId></ArticleIdList></Reference><Reference><Citation>Minenkova O, Santapaola D, Milazzo FM, Anastasi AM, Battistuzzi G, Chiapparino C, et al. Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy. Mol Ther. (2022) 30(5):1979&#x2013;93. 10.1016/j.ymthe.2022.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.013</ArticleId><ArticleId IdType="pmc">PMC8837488</ArticleId><ArticleId IdType="pubmed">35167974</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain C, Dumont J, Dumoulin M. Camelid single-domain antibody fragments: uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena. Biochimie. (2015) 111:82&#x2013;106. 10.1016/j.biochi.2015.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2015.01.012</ArticleId><ArticleId IdType="pubmed">25656912</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarty R, Goel S, Cai W. Nanobody: the &#x201c;magic bullet&#x201d; for molecular imaging? Theranostics. (2014) 4(4):386&#x2013;98. 10.7150/thno.8006</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.8006</ArticleId><ArticleId IdType="pmc">PMC3936291</ArticleId><ArticleId IdType="pubmed">24578722</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto GV, Jara R, Watterson D, Modhiran N, Amarilla AA, Himelreichs J, et al. Potent neutralization of clinical isolates of SARS - CoV - 2 D614 and G614 variants by a monomeric, sub - nanomolar affinity nanobody. Sci Rep. (2021) 11:1&#x2013;14. 10.1038/s41598-021-82833-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-82833-w</ArticleId><ArticleId IdType="pmc">PMC7870875</ArticleId><ArticleId IdType="pubmed">33558635</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandschoot P, Stortelers C, Beirnaert E, Iba&#xf1;ez LI, Schepens B, Depla E, et al. Nanobodies&#xae;: new ammunition to battle viruses. Antiviral Res. (2011) 92(3):389&#x2013;407. 10.1016/j.antiviral.2011.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2011.09.002</ArticleId><ArticleId IdType="pubmed">21939690</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela-Nieto G, Miranda-Chacon Z, Salinas-Rebolledo C, Jara R, Cuevas A, Berking A, et al. Nanobodies: cOVID-19 and future perspectives. Front in Drug Discov. (2022) 2:1&#x2013;11. 10.3389/fddsv.2022.927164</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fddsv.2022.927164</ArticleId></ArticleIdList></Reference><Reference><Citation>Syv&#xe4;nen S, Fang XT, Faresj&#xf6; R, Rokka J, Lannfelt L, Olberg DE, et al. Fluorine-18-Labeled antibody ligands for PET imaging of amyloid-&#x3b2; in brain. ACS Chem Neurosci. (2020) 7(2):1&#x2013;16. 10.1021/acschemneuro.0c00652</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00652</ArticleId><ArticleId IdType="pmc">PMC7747219</ArticleId><ArticleId IdType="pubmed">33236886</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe9;en EJL, Edem PE, N&#xf8;rregaard K, J&#xf8;rgensen JT, Shalgunov V, Kjaer A, et al. Pretargeting in nuclear imaging and radionuclide therapy: improving efficacy of theranostics and nanomedicines. Biomaterials. (2018) 179:209&#x2013;45. 10.1016/j.biomaterials.2018.06.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2018.06.021</ArticleId><ArticleId IdType="pubmed">30007471</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudt M, Herth MM, Poulie CBM. Pretargeted theranostics. In: Eppard E, editor. Theranostics - an old concept in new clothing. London: IntechOpen;  (2021). p. 1&#x2013;19. Available at:
https://www.intechopen.com/online-first/pretargeted-theranostics</Citation></Reference><Reference><Citation>Rossin R, van Duijnhoven SMJ, L&#xe4;ppchen T, van den Bosch SM, Robillard MS. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction. Mol Pharm. (2014) 11(9):3090&#x2013;6. 10.1021/mp500275a</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/mp500275a</ArticleId><ArticleId IdType="pubmed">25077373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Vannam R, Lambert WD, Xie Y, Wang H, Giglio B, et al. Hydrophilic 18 F-labeled trans &#x2212;5-oxocene (oxoTCO) for efficient construction of PET agents with improved tumor-to-background ratios in neurotensin receptor (NTR) imaging. Chemical Communications. (2019) 55(17):2485&#x2013;8. 10.1039/C8CC09747J</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C8CC09747J</ArticleId><ArticleId IdType="pmc">PMC7347157</ArticleId><ArticleId IdType="pubmed">30735213</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaraj NK, Upadhyay R, Haun JB, Hilderbrand SA, Weissleder R. Fast and sensitive pretargeted labeling of cancer cells through a tetrazine/trans-cyclooctene cycloaddition. Angew Chem Int Ed. (2009) 48:7013&#x2013;6. 10.1002/anie.200903233</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.200903233</ArticleId><ArticleId IdType="pmc">PMC2790075</ArticleId><ArticleId IdType="pubmed">19697389</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll L, Evans HL, Aboagye EO, Spivey AC. Bioorthogonal chemistry for pre-targeted molecular imaging-progress and prospects. Org Biomol Chem. (2013) 11:5772&#x2013;81. 10.1039/c3ob40897c</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c3ob40897c</ArticleId><ArticleId IdType="pubmed">23907155</ArticleId></ArticleIdList></Reference><Reference><Citation>Haun JB, Devaraj NK, Hilderbrand SA, Lee H, Weissleder R. Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat Nanotechnol. (2010) 5(9):660&#x2013;5. 10.1038/nnano.2010.148</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nnano.2010.148</ArticleId><ArticleId IdType="pmc">PMC2934903</ArticleId><ArticleId IdType="pubmed">20676091</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-V&#xe1;zquez R, Battisti UM, J&#xf8;rgensen JT, Shalgunov V, Hvass L, Stares DL, et al. Direct cu-mediated aromatic18F-labeling of highly reactive tetrazines for pretargeted bioorthogonal PET imaging. Chem Sci. (2021) 12(35):11668&#x2013;75. 10.1039/D1SC02789A</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1SC02789A</ArticleId><ArticleId IdType="pmc">PMC8442695</ArticleId><ArticleId IdType="pubmed">34659701</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt T, John CS, Ruckle JL, Vuong LT. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans&#x2013;a practical guide. Expert Opin Drug Deliv. (2017) 14(5):657&#x2013;72. 10.1080/17425247.2016.1227786</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2016.1227786</ArticleId><ArticleId IdType="pubmed">27564533</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Department of Health and Human Services- Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Microdose radiopharmaceutical diagnostic drugs&#x202f;: nonclinical study recommendations guidance for industry. Guideline. (2018):4. fda.gov, docket nr. FDA-2017-D-5297. Available at:
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm</Citation></Reference><Reference><Citation>Cardinale J, Giammei C, Jouini N, Mindt TL. Bioconjugation methods for radiopharmaceutical chemistry. In: Lewis JS, Windhorst AD, Zeglis BM, editors. Radiopharmaceutical chemistry. Cham: Springer International Publishing;  (2019). p. 449&#x2013;66. Available at:
http://link.springer.com/10.1007/978-3-319-98947-1_25</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-98947-1_25</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook BE, Adumeau P, Membreno R, Carnazza KE, Brand C, Reiner T, et al. Pretargeted PET imaging using a site-specifically labeled immunoconjugate. Bioconjug Chem. (2016) 27:1789&#x2013;95. 10.1021/acs.bioconjchem.6b00235</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.bioconjchem.6b00235</ArticleId><ArticleId IdType="pmc">PMC5102008</ArticleId><ArticleId IdType="pubmed">27356886</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalgunov V, Lopes van den Broek S, Andersen IV, Garcia Vazquez R, Raval N, Palner M, et al. Pretargeted imaging beyond the blood-brain barrier. ChemRxiv; (2022). Cambridge (This content is a preprint and has not been peer-reviewed.)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10034008</ArticleId><ArticleId IdType="pubmed">36970152</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. (2020) 369(6510):1501&#x2013;5. 10.1126/science.abd0826</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0826</ArticleId><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-L&#xf3;pez E, Schuhmacher AJ. Transportation of single-domain antibodies through the blood&#x2013;brain barrier. Biomolecules. (2021) 11(8):1&#x2013;23. 10.3390/biom11081131</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11081131</ArticleId><ArticleId IdType="pmc">PMC8394617</ArticleId><ArticleId IdType="pubmed">34439797</ArticleId></ArticleIdList></Reference><Reference><Citation>Peltek OO, Muslimov AR, Zyuzin M, Timin AS. Current outlook on radionuclide delivery systems: from design consideration to translation into clinics. J Nanobiotechnology. (2019) 17(90):1&#x2013;34. 10.1186/s12951-019-0524-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-019-0524-9</ArticleId><ArticleId IdType="pmc">PMC6704557</ArticleId><ArticleId IdType="pubmed">31434562</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz-Fontela C, Widerspick L, Albrecht RA, Beer M, Carroll MW, de Wit E, et al. Advances and gaps in SARS-CoV-2 infection models. Lazear HM, editor. PLoS Pathog. (2022) 18(1):e1010161. 10.1371/journal.ppat.1010161</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010161</ArticleId><ArticleId IdType="pmc">PMC8757994</ArticleId><ArticleId IdType="pubmed">35025969</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandamooz S, Jurek B, Meinung CP, Baharvand Z, Sahebi Shahem-abadi A, Haerteis S, et al. Experimental models of SARS-CoV-2 infection: possible platforms to study COVID-19 pathogenesis and potential treatments. Annu Rev Pharmacol Toxicol. (2022) 62(1):25&#x2013;53. 10.1146/annurev-pharmtox-121120-012309</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-121120-012309</ArticleId><ArticleId IdType="pubmed">33606962</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>